Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.

@article{Ode2007MechanismOD,
  title={Mechanism of drug resistance due to N88S in CRF01\_AE HIV-1 protease, analyzed by molecular dynamics simulations.},
  author={Hirotaka Ode and Shou Matsuyama and Masayuki Hata and Tyuji Hoshino and Junko Kakizawa and Wataru Sugiura},
  journal={Journal of medicinal chemistry},
  year={2007},
  volume={50 8},
  pages={
          1768-77
        }
}
Nelfinavir (NFV) is a currently available HIV-1 protease (PR) inhibitor. Patients in whom NFV treatment has failed predominantly carry D30N mutants of HIV-1 PRs if they have been infected with the subtype B virus. In contrast, N88S mutants of HIV-1 PRs predominantly emerge in patients in whom NFV treatment has failed and who carry the CRF01_AE virus. Both D30N and N88S confer resistance against NFV. However, it remains unclear why the nonactive site mutation N88S confers resistance against NFV… 
View on PubMed
mitizane.ll.chiba-u.jp
51 Citations
Background Citations
9
Methods Citations
6
Results Citations
2

Figures and Tables from this paper

51 Citations

Citation Type

Citation Type

Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease
TLDR
It is proposed that DBM protease showed greater flexibility and the flap separation was greater with respect to the wild type protease, which may be responsible for the decreased interaction of Nelfinavir with the cavity residues, thus explaining the decreased binding affinity.
Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
TLDR
This work explored the resistance mechanism against SQV due to active site mutations G48V and V82F in CRF01_AE (AE) protease, and found that the substitution of phenylalanine at position 82 induces conformational changes in the 80's loop and the flap region, thereby favoring the binding of SQV.
Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations
TLDR
Light is shed on the effect of active, non-active site mutations and their cooperative effects in AE protease using molecular dynamics simulations and binding free energy calculations to investigate the mechanism of resistance against indinavir.
The Effect of Clade-Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways
TLDR
These studies show that sequence polymorphisms within clades can alter protease activity and inhibitor binding and are capable of altering the pathway to inhibitor resistance.
Effect of Natural Polymorphisms in the HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility
TLDR
It is suggested that screening for potential HS-linked polymorphisms as well as preexisting drug resistance mutations in treatment-naïve patients may guide the choice of ARVs for the best treatment outcome.
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains
TLDR
S68G may be a natural polymorphism and compensatory mutation of K65R selected by NRTIs in the CRF01_AE strain of HIV-1, which does not affect susceptibility to NRTI; however, it improves the replication fitness of K 65R mutants.
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains
TLDR
S68G may be a natural polymorphism and compensatory mutation of K65R selected by NRTIs in the CRF01_AE strain of HIV-1, which does not affect susceptibility to NRTI; however, it improves the replication fitness of K 65R mutants.
Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors
TLDR
Estimating the effect of both binding pocket and distant mutations on inhibitor binding free energy using alchemical calculations can reproduce their effect on the experimentally measured I C 50 values indicates valuable insights on interplay between primary and background mutations and mechanisms how they affect inhibitor binding.
Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
TLDR
The changes of binding energies of the mutants from the wild-type protease are shown to be correlated with the mutant resistivity previously reported by the phenotypic experiments.
A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir
TLDR
The presence of the N88S mutation and associated amprenvir hypersensitivity may be useful in predicting an improved clinical response to amprenavir salvage therapy, and is confirmed in site-directed mutagenesis studies.
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
TLDR
Structural analysis of atazanavir bound to a pretherapy B protease showed that the ability of at zealousavir to maintain its binding affinity for variants containing some resistance mutations is due to its unique interactions with flap residues.
Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
TLDR
The difference in levels of resistance to the three inhibitors has been explained from energetic and structural viewpoints, which provides the suggestion for promising drugs keeping its efficacy even for the L90M mutant.
Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.
TLDR
Cross-sectionally compared patterns of the drug-resistant point mutations in patients infected with either subtype B or CRF01_AE (subtype E) among patients who acquired HIV by sexual transmission in Japan.
Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy
TLDR
It is found that Val82 interacts more closely with the drugs than with the natural substrate peptides, which suggests that future inhibitor design may reduce the probability of the appearance of drug-resistant mutations by targeting residues that are essential for substrate recognition.
Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations
TLDR
The first computational study of the clinically relevant E35D mutation of HIV-1 protease in its unbound conformation and complexed with the clinical inhibitor amprenavir and a sample substrate is reported, giving a plausible explanation for its ability to increase the level of resistance.
Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
TLDR
This paper characterized a multiple-drug-resistant mutant of the HIV-1 protease that affects indinavir, nelfinavIR, saquinavir, ritonavIR, amprenavir and lopinavir and provides a set of thermodynamic guidelines for the design of inhibitors with a lower susceptibility to this type of mutations.
Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance
TLDR
The HIV‐1 protease crystal structure of the G48V/L90M double mutant in complex with saquinavir at 2.6 Å resolution is solved and shows that to accommodate a valine side chain at position 48, the inhibitor moves away from the protease, resulting in the formation of larger gaps between the inhibitor P3 subsite and the flap region of the enzyme.
...
1
2
3
4
5
...